Download oncology development pipeline

ONCOLOGY DEVELOPMENT PIPELINE
PROGRAM
DESCRIPTION
DEVELOPMENT RIGHTS
DISEASE(S) UNDER INVESTIGATION
CD30 Antibody Drug Conjugate
Global†‡
Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma,
Mature T-Cell Lymphoma
VECTIBIX®
Anti-EGFR Antibody
Japan Only
Colorectal Cancer
LEUPLIN®
LH-RH Agonist
Japan Only
Prostate Cancer, Breast Cancer, new formulation
NINLARO®
Proteasome Inhibitor
Global
Multiple Myeloma, Amyloidosis
TAK-228
TORC1/TORC2 Inhibitor
Global
Breast Cancer, Renal Cell Carcinoma, Endometrial Cancer
PEVONEDISTAT
Nedd8-Activating Enzyme Inhibitor
Global
High-Risk Myelodysplastic Syndrome,
Acute Myelogenous Leukemia
TAK-659
SYK/FLT-3 Kinase Inhibitor
Global
Lymphoma, Acute Myelogenous Leukemia
Solid Tumors
TAK-117
PI3K Alpha Inhibitor
Global
Non-Small Cell Lung Cancer
TAK-580
Pan-Raf Kinase Inhibitor
Global
Solid Tumors
TAK-243
UAE Inhibitor
Global
Solid Tumors
TAK-931
CDC7 Inhibitor
Global
Solid Tumors
XMT-1522
HER2 Dolaflexin ADC
Ex-US, Ex-Canada*
Breast Cancer
ADCETRIS®
(brentuximab vedotin)
†‡
(panitumumab)†
(Leuprorelin acetate)
(ixazomib)
‡ADCETRIS® is co-developed by Takeda and Seattle Genetics, Inc.
†In-Licensed
*
XMT-1522 is co-developed by Takeda and Mersana Therapeutics
All registered trademarks are the sole property of their respective owners.
Last updated 10/20/2016
OMS/ONC/15/0015(4)
PHASE 1
PHASE 2
PHASE 3